MA52364A - Inhibiteurs doubles d'atm et d'adn-pk pour une utilisation en thérapie antitumorale - Google Patents
Inhibiteurs doubles d'atm et d'adn-pk pour une utilisation en thérapie antitumoraleInfo
- Publication number
- MA52364A MA52364A MA052364A MA52364A MA52364A MA 52364 A MA52364 A MA 52364A MA 052364 A MA052364 A MA 052364A MA 52364 A MA52364 A MA 52364A MA 52364 A MA52364 A MA 52364A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitors
- dna
- tumor therapy
- dual atm
- atm
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810359447.6A CN110386932A (zh) | 2018-04-20 | 2018-04-20 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| US201862665296P | 2018-05-01 | 2018-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52364A true MA52364A (fr) | 2021-03-03 |
Family
ID=68283636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052364A MA52364A (fr) | 2018-04-20 | 2019-04-17 | Inhibiteurs doubles d'atm et d'adn-pk pour une utilisation en thérapie antitumorale |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12187742B2 (fr) |
| EP (2) | EP4327877A3 (fr) |
| JP (1) | JP7366996B2 (fr) |
| KR (1) | KR20210027251A (fr) |
| CN (2) | CN110386932A (fr) |
| BR (1) | BR112020021323A2 (fr) |
| CA (1) | CA3096732A1 (fr) |
| MA (1) | MA52364A (fr) |
| MX (1) | MX2020010942A (fr) |
| SG (1) | SG11202010212RA (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016057931A1 (fr) | 2014-10-10 | 2016-04-14 | The Research Foundation For The State University Of New York | Trifluorométhoxylation d'arènes via une migration intramoléculaire du groupe trifluorométhoxy |
| WO2019201283A1 (fr) | 2018-04-20 | 2019-10-24 | Xrad Therapeutics, Inc. | Inhibiteurs doubles d'atm et d'adn-pk pour une utilisation en thérapie antitumorale |
| EP4003345B1 (fr) * | 2019-07-30 | 2024-12-04 | XRad Therapeutics, Inc. | Inhibiteurs doubles de l'atm et de l'adn-pk destinés à une utilisation en thérapie antitumorale |
| CN114746421A (zh) * | 2019-11-19 | 2022-07-12 | 南京明德新药研发有限公司 | 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用 |
| CA3159110A1 (fr) * | 2019-11-22 | 2021-05-27 | Kevin X Chen | Composes spiro pyrimidopyrrole et leurs derives en tant qu'inhibiteurs de la proteine dna-pk |
| WO2021136462A1 (fr) * | 2019-12-31 | 2021-07-08 | 成都百裕制药股份有限公司 | Dérivés furane et leur application en médecine |
| WO2021197339A1 (fr) * | 2020-03-30 | 2021-10-07 | 南京明德新药研发有限公司 | Forme cristalline de composé de quinopyrrolidine-2-one servant d'inhibiteur d'atm et son utilisation |
| CN114634521A (zh) * | 2020-12-15 | 2022-06-17 | 首药控股(北京)股份有限公司 | Dna-pk选择性抑制剂及其制备方法和用途 |
| EP4676465A1 (fr) * | 2023-03-06 | 2026-01-14 | XRAD Holding Cayman Limited | Méthodes de traitement du cancer |
| WO2025247391A1 (fr) * | 2024-05-31 | 2025-12-04 | Hutchmed Limited | Nouveaux inhibiteurs de pi3k et/ou pikk, conjugués anticorps-médicament les comprenant et leurs utilisations |
| WO2026006954A1 (fr) * | 2024-07-01 | 2026-01-08 | Xrad Holding Cayman Limited | Inhibiteurs doubles d'atm et de dna-pk destinés à être utilisés dans une thérapie antitumorale |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2589935A1 (fr) | 2004-12-09 | 2006-06-15 | Regents Of The University Of Minnesota | Nucleosides presentant une activite antivirale et anticancereuse |
| MX341849B (es) | 2006-06-01 | 2016-09-05 | Sanofi Aventis | Nitrilos espirociclicos como inhibidores de proteasa. |
| US7981893B2 (en) | 2006-10-19 | 2011-07-19 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| EP2303890A4 (fr) * | 2008-06-19 | 2012-04-11 | Progenics Pharm Inc | Inhibiteurs de phosphatidylinositol 3 kinase |
| EP2350053B1 (fr) * | 2008-10-17 | 2013-12-11 | Whitehead Institute For Biomedical Research | Modulateurs de Complexes de MTOR |
| JP2012528829A (ja) * | 2009-06-04 | 2012-11-15 | ノバルティス アーゲー | １Ｈ−イミダゾ［４，５−ｃ］キノリノン化合物 |
| WO2011071716A1 (fr) | 2009-12-07 | 2011-06-16 | Boehringer Ingelheim International Gmbh | Composés hétérocycliques contenant un cœur indole |
| CN102399218A (zh) | 2010-09-16 | 2012-04-04 | 和记黄埔医药（上海）有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
| KR20140014104A (ko) * | 2010-12-06 | 2014-02-05 | 피라말 엔터프라이지즈 리미티드 | 치환된 이미다조퀴놀린 유도체 |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| AR089929A1 (es) | 2012-02-10 | 2014-10-01 | Actelion Pharmaceuticals Ltd | Proceso para manufacturar un derivado de naftiridina |
| LT3495367T (lt) * | 2012-06-13 | 2021-02-25 | Incyte Holdings Corporation | Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai |
| CN103936762B (zh) * | 2013-01-17 | 2016-02-24 | 上海汇伦生命科技有限公司 | 吗啉并喹啉类化合物，其制备方法和用途 |
| CN103880844A (zh) * | 2014-04-09 | 2014-06-25 | 彭正中 | 一种喹啉酮类新化合物及其制备方法与用途 |
| NO2714752T3 (fr) * | 2014-05-08 | 2018-04-21 | ||
| AU2015276699B2 (en) * | 2014-06-17 | 2019-10-10 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyridino[1,2-a]pyrimidone analogue used as PI3K inhibitor |
| CN105461712B (zh) * | 2014-06-17 | 2019-01-29 | 上海嘉坦医药科技有限公司 | 作为mTOR/PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物 |
| CN105461711B (zh) * | 2014-06-17 | 2018-11-06 | 正大天晴药业集团股份有限公司 | 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物 |
| BR112016029825B1 (pt) | 2014-06-17 | 2020-10-27 | Cisen Pharmaceutical Co., Ltd. | composto |
| KR20170048410A (ko) | 2014-09-17 | 2017-05-08 | 베르선 코포레이션 | 세린 프로테아제 저해제로서의 피라졸릴-치환된 피리돈 화합물 |
| DK3560924T3 (da) | 2015-04-02 | 2021-06-28 | Merck Patent Gmbh | Imidazolonylquinoliner og deres anvendelse som atm-kinase-inhibitorer |
| WO2016186453A1 (fr) * | 2015-05-20 | 2016-11-24 | Kainos Medicine, Inc. | Dérivés de quinoléine à utiliser en tant qu'inhibiteurs de bromodomaine |
| GB201519406D0 (en) * | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| GB201519568D0 (en) | 2015-11-05 | 2015-12-23 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| ES2904557T3 (es) | 2016-01-20 | 2022-04-05 | Biogen Ma Inc | Agentes inhibidores de irak4 |
| WO2017162611A1 (fr) * | 2016-03-21 | 2017-09-28 | Astrazeneca Ab | Composés quinoline-3-carboxamide et leur utilisation pour traiter le cancer |
| TWI696615B (zh) | 2016-05-05 | 2020-06-21 | 瑞士商伊蘭科動物健康公司 | 雜芳基-1,2,4-三唑及雜芳基-三唑化合物 |
| GB201608227D0 (en) * | 2016-05-11 | 2016-06-22 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| MX391410B (es) * | 2018-09-30 | 2025-03-21 | Medshine Discovery Inc | Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos. |
| EP4003345B1 (fr) | 2019-07-30 | 2024-12-04 | XRad Therapeutics, Inc. | Inhibiteurs doubles de l'atm et de l'adn-pk destinés à une utilisation en thérapie antitumorale |
-
2018
- 2018-04-20 CN CN201810359447.6A patent/CN110386932A/zh active Pending
-
2019
- 2019-04-17 BR BR112020021323-3A patent/BR112020021323A2/pt not_active IP Right Cessation
- 2019-04-17 JP JP2021506031A patent/JP7366996B2/ja active Active
- 2019-04-17 EP EP23202655.9A patent/EP4327877A3/fr not_active Withdrawn
- 2019-04-17 CN CN201980040733.9A patent/CN112469720B/zh active Active
- 2019-04-17 EP EP19787882.0A patent/EP3784671B1/fr active Active
- 2019-04-17 KR KR1020207033463A patent/KR20210027251A/ko not_active Withdrawn
- 2019-04-17 SG SG11202010212RA patent/SG11202010212RA/en unknown
- 2019-04-17 CA CA3096732A patent/CA3096732A1/fr active Pending
- 2019-04-17 MA MA052364A patent/MA52364A/fr unknown
- 2019-04-17 MX MX2020010942A patent/MX2020010942A/es unknown
-
2020
- 2020-10-19 US US17/074,425 patent/US12187742B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202010212RA (en) | 2020-11-27 |
| MX2020010942A (es) | 2021-01-15 |
| EP4327877A3 (fr) | 2024-04-24 |
| CN112469720A (zh) | 2021-03-09 |
| AU2019254980A1 (en) | 2020-12-03 |
| EP3784671A1 (fr) | 2021-03-03 |
| CN112469720B (zh) | 2024-03-29 |
| JP7366996B2 (ja) | 2023-10-23 |
| KR20210027251A (ko) | 2021-03-10 |
| EP3784671A4 (fr) | 2021-11-17 |
| CN110386932A (zh) | 2019-10-29 |
| JP2021522316A (ja) | 2021-08-30 |
| EP3784671B1 (fr) | 2023-10-11 |
| US20220315606A1 (en) | 2022-10-06 |
| BR112020021323A2 (pt) | 2021-01-19 |
| EP4327877A2 (fr) | 2024-02-28 |
| US12187742B2 (en) | 2025-01-07 |
| CA3096732A1 (fr) | 2019-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3784671A4 (fr) | Inhibiteurs doubles d'atm et d'adn-pk pour une utilisation en thérapie antitumorale | |
| EP4003345A4 (fr) | Inhibiteurs doubles de l'atm et de l'adn-pk destinés à une utilisation en thérapie antitumorale | |
| MA52963A (fr) | Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation | |
| MA50082A (fr) | Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer | |
| IL281999A (en) | YAP/TAZ-TEAD interaction inhibitors and their use in cancer therapy | |
| MA51848A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52765A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52501A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52496A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA50077A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| EP4034094A4 (fr) | Inhibiteurs de phosphodiestérase et leur utilisation | |
| MA48772A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| EP3710430A4 (fr) | Inhibiteurs d'acss2 et leurs procédés d'utilisation | |
| MA52542A (fr) | Thérapie cellulaire adoptive | |
| MA46995A (fr) | Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase | |
| EP3430057A4 (fr) | Utilisation d'inhibiteurs d'ape1/ref-1 dans des polythérapies pour le traitement du cancer | |
| LT3806898T (lt) | Gremlin-1 antagonistas, skirtas naudoti vėžio gydymui | |
| IL290130A (en) | Treatment of immune evasive tumors | |
| MA55799A (fr) | Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 | |
| EP3645020A4 (fr) | Compositions et procédés pour la thérapie cellulaire adoptive | |
| IL286482A (en) | Expanded nk cell fractions for transplantation in combination therapy | |
| MA55504A (fr) | Anticorps dirigés contre le liraglutide et leur utilisation | |
| ZA202000904B (en) | Mpo inhibitors for use in medicine | |
| IL283687A (en) | usp19 inhibitors and their use for therapeutic purposes | |
| EP3802569A4 (fr) | Peptides de pénétration cellulaire et leurs procédés d'utilisation |